Master Cyclophosphamide with Picmonic for Medicine

It is important to know that cyclophosphamide requires bioactivation by the liver before having its therapeutic effects. As a prodrug, it is converted by liver cytochrome P450 (CYP) enzymes to form the metabolite 4-hydroxy cyclophosphamide that has chemotherapeutic activity.

Cyclophosphamide is an alkylating agent, meaning it works by cross-linking DNA. It does so because alkylating agents add an alkyl group to DNA, and specifically, cyclophosphamide adds an alkyl group at the guanine N7 position. Once DNA is cross-linked, it is inhibited from replicating.

This alkylating agent adds an alkyl group to the guanine base pair at the number 7 nitrogen atom of the imidazole ring, specifically. Thus, it is said that this drug alkylates, and leads to cross-links at the guanine N7 position.

Because cyclophosphamide depresses leukocyte replication, this medication can be used for various autoimmune disorders. This includes rheumatoid arthritis, SLE, and multiple sclerosis. It can be used for autoimmune vasculitis disorders, such as microscopic polyangiitis and polyarteritis nodosa. Cyclophosphamide can also be used for minimal change disease.

This drug is used to treat various leukemias, such as chronic lymphocytic leukemia and chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis). It is also used for acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (Cyclophosphamide given during remission is effective in prolonging its duration).

Cyclophosphamide is one of the drugs used to treat lymphomas such as Hodgkin's, non-Hodgkin's and Burkitt's lymphomas.

This drug is used for various solid tumors, such as breast cancers, ovarian and cervical cancers, and testicular cancers. It can be used for soft-tissue malignancies (sarcomas).

This medication can cause bone marrow toxicity, which can manifest as myelosuppression. This can lead to decreased erythrocytes (RBCs), leukocytes (WBCs), and thrombocytes (platelets) in patients. This is due to the fact that this drug interferes with DNA replication.

A highly tested side effect of cyclophosphamide use is the development of hemorrhagic cystitis. Cyclophosphamide causes the chemical acrolein to be produced, and acrolein is toxic to the bladder epithelium (leading to hemorrhagic cystitis). Patients display microscopic or gross hematuria and occasionally dysuria. Risks of hemorrhagic cystitis can be minimized with adequate fluid intake, avoidance of nighttime dosage, and mesna, which binds and detoxifies acrolein. It should also be noted that this drug is associated with an increased incidence of transitional cell carcinoma (TCC).

Remember that Mesna is a highly tested treatment for the side effect of hemorrhagic cystitis associated with this medication's use. Mesna binds to acrolein, a toxic metabolite of cyclophosphamide, working to inhibit the hemorrhagic cystitis that can develop in patients. Other mitigating precautions patients can take include adequate hydration and avoiding nighttime dosing of this medication.